Concomitant medications for cancer treatment

摘要

This specification describes a combination drug comprising a therapeutically effective amount of a first agent and a therapeutically effective amount of a second agent, wherein the first agent is an inhibitor of ALK, ROS1, TrkA, TrkB, or TrkC activity, or A method of using the combination in combination and treatment of patients with cancer is described. [Selection] Figure 1